Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma
Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCC FORT LEE, N.J., Oct. 14, 2026 (GLOBE...